Which dietary supplements are contraindicated for patients undergoing cancer treatment (e.g., chemotherapy, radiation therapy, targeted therapy, or immunotherapy)?

Contraindicated Supplements During Cancer Treatment

Patients undergoing cancer treatment should avoid antioxidant supplements (vitamins A, C, E, beta-carotene, coenzyme Q10), St. John's wort, high-dose vitamin B12, iron supplements, and vitamin E, as these have been associated with reduced treatment efficacy, increased recurrence, and worse survival outcomes. 12

High-Risk Supplements to Avoid

Antioxidants (Strong Evidence Against Use)

• Vitamin E: Associated with higher incidence of recurrence and second primary cancers in head and neck cancer patients receiving radiation therapy 2. A large prospective study found antioxidant use both before and during chemotherapy increased hazard of recurrence (HR 1.41) and death (HR 1.40) 1
• Beta-carotene: Increases risk of lung and stomach cancer; increases overall mortality 3
• Vitamins A, C, and carotenoids: Part of the antioxidant group linked to poorer outcomes during chemotherapy 1
• Coenzyme Q10: Included in antioxidants that may protect tumor cells from cytotoxic therapy 45

Mechanism of harm: Antioxidants may reduce the oxidative damage that chemotherapy and radiation therapy intentionally create to kill cancer cells, potentially protecting tumor cells alongside normal cells 45

St. John's Wort (Critical Drug Interaction)

• Reduces chemotherapy efficacy: Increases clearance of drugs metabolized by cytochrome P450 3A4
• Specific example: Reduced plasma levels of SN-38 (active metabolite of irinotecan) by 42% in cancer patients 2
• This represents a pharmacokinetic interaction that can render treatment ineffective 6

Vitamin B12 (Strong Evidence of Harm)

• Significantly associated with poorer outcomes: Use both before and during chemotherapy linked to worse disease-free survival (HR 1.83) and overall survival (HR 2.04) 1
• This finding comes from a large cooperative group clinical trial with rigorous methodology

Iron Supplements

• Increases recurrence risk: Use during chemotherapy associated with recurrence (HR 1.79); use both before and during treatment showed HR 1.91 1
• Similar negative associations for overall survival

Folic Acid (Context-Dependent Risk)

• May foster progression of pre-malignant colonic lesions after carcinogenic process has been initiated 2
• Raises concerns about promoting recurrences and metastases 2

Supplements Requiring Caution

High-Dose Vitamins and Minerals

• The National Cancer Institute strongly urges cancer patients to avoid vitamin and mineral supplements during treatment or take them only under physician guidance 2
• Distinction: A standard multivitamin at 100% RDA may be acceptable for patients unable to eat healthfully, but high-dose individual supplements should be avoided 2

Critical Communication Gap

31% to 68% of cancer patients using supplements do not discuss this with their physicians 22. This is dangerous because:

• Physicians often fail to ask about supplement use 2
• Patients fear physician opposition or perceive indifference 2
• Potential interactions with adjuvant therapy go unrecognized 2

Recommended Clinical Approach

What Clinicians Should Do:

1. Proactively ask specific questions using the framework from the 2022 guideline 7:

   • "Are you currently taking or considering taking supplements, such as vitamins and minerals (for example vitamin E or D, calcium) or herbal therapies (for example turmeric, ginseng, St. John's wort)?"
   • Ask about dose, frequency, and who recommended the supplement

2. Normalize the conversation: Acknowledge that supplement use is common (64-81% of cancer survivors use them) 2 and create a non-judgmental space for disclosure 7

3. Document everything: Record supplement use in the medical chart, as physicians frequently fail to do this even when patients mention it 2

Exception: Documented Deficiencies

• Supplements should only be used to correct laboratory-confirmed deficiencies 8
• Examples where substitution may be appropriate: selenium, iron, vitamin D when deficiency is documented 8
• This is fundamentally different from prophylactic or "health-promoting" supplementation

Common Pitfalls to Avoid

• Assuming "natural" means safe: Patients perceive supplements as beneficial and harmless, but evidence shows otherwise 25
• Failing to ask repeatedly: Supplement use should be assessed across the entire disease trajectory, not just at diagnosis 7
• Accepting vague answers: Get specific names, doses, and frequencies—not just "I take vitamins" 7
• Ignoring over-the-counter products: Many patients don't consider these "real medicine" worth mentioning

The Bottom Line

The evidence consistently supports discouraging antioxidant and most individual supplement use during active cancer treatment 45. While multivitamins at standard doses were not associated with worse outcomes 1, the safest approach is to avoid supplementation beyond correcting documented deficiencies unless participating in a clinical trial specifically studying the supplement in question.